Chuang W.-L.Chien R.-N.Peng C.-Y.Chang T.-T.Lo G.-H.Sheen I.-S.Wang H.-Y.Chen J.-J.Yang J.C.Knox S.J.Gao B.Garrison K.L.Mo H.Pang P.S.Hsu Y.-C.Hu T.-H.Chu C.-J.JIA-HORNG KAO2021-09-042021-09-0420160815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979523519&doi=10.1111%2fjgh.13305&partnerID=40&md5=151e7af74332342779ccbb01e4b15738https://scholars.lib.ntu.edu.tw/handle/123456789/581910Background and Aimhepatitis C virus (HCV); infection; ledipasvir; sofosbuvir; Taiwan[SDGs]SDG3glucose; hemoglobin A1c; ledipasvir plus sofosbuvir; benzimidazole derivative; carbamic acid derivative; drug combination; fluorene derivative; fused heterocyclic rings; ledipasvir; sofosbuvir; sofosbuvir-velpatasvir drug combination; tablet; adenomyosis; adult; aged; Article; cancer patient; chronic hepatitis C; compensated liver cirrhosis; coughing; dizziness; drug efficacy; drug safety; endometriosis; fatigue; female; glucose blood level; headache; hemoglobin blood level; Hepatitis C virus genotype 1; human; hyperglycemia; hyperkalemia; laboratory test; major clinical study; malaise; male; multicenter study; nausea; neutrophil count; open study; personal experience; phase 3 clinical trial; priority journal; rhinopharyngitis; side effect; small cell lung cancer; Taiwanese; treatment duration; treatment response; upper respiratory tract infection; clinical trial; drug combination; genetics; genotype; Hepacivirus; Hepatitis C, Chronic; middle aged; tablet; Taiwan; treatment outcome; virology; Adult; Aged; Benzimidazoles; Carbamates; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Tablets; Taiwan; Treatment Outcomejournal article10.1111/jgh.13305268419302-s2.0-84979523519